These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 8879373)

  • 41. Chemotherapy versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-institutional Propensity Score Matching Analysis.
    Ji JH; Kim YS; Park I; Lee SI; Kim RB; Park JO; Oh SY; Hwang IG; Jang JS; Song HN; Kang JH
    Cancer Res Treat; 2018 Jul; 50(3):791-800. PubMed ID: 28838033
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase II trial of raltitrexed (Tomudex) in advanced pancreatic and biliary carcinoma.
    François E; Hebbar M; Bennouna J; Mayeur D; Perrier H; Dorval E; Martin C; Bourgeois H; Barthélemy P; Douillard JY
    Oncology; 2005; 68(4-6):299-305. PubMed ID: 16020956
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer.
    Garcia AA; Leichman L; Baranda J; Pandit L; Lenz HJ; Leichman CG
    Int J Gastrointest Cancer; 2003; 34(2-3):79-86. PubMed ID: 15361639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. A longitudinal study.
    Glimelius B; Graf W; Hoffman K; Påhlman L; Sjödén PO; Wennberg A
    Acta Oncol; 1992; 31(6):645-51. PubMed ID: 1281650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of advanced pancreatic cancer with epirubicin, 5-fluorouracil and 1-leucovorin: a phase II study.
    Raderer M; Kornek GV; Hejna MH; Weinlaender G; Vorbeck F; Fiebiger WC; Scheithauer W
    Ann Oncol; 1997 Aug; 8(8):797-9. PubMed ID: 9332689
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prospective randomized trial comparing modified FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus 5-FU alone for the treatment of non-resectable pancreatic and biliary tract carcinomas (the 1st trial in non-resectable patients). Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract].
    Takada T; Kato H; Sasaki M; Matsushiro T; Yamauchi H; Kajihara T; Watanabe G; Hanaue H; Yoshida K; Shimizu T
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1295-301. PubMed ID: 1503483
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer.
    Chiou TJ; Tung SL; Hsieh RK; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Jpn J Clin Oncol; 1998 May; 28(5):318-22. PubMed ID: 9703859
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
    Caroli-Bosc FX; Van Laethem JL; Michel P; Gay F; Hendlisz A; Forget F; Bleiberg H
    Eur J Cancer; 2001 Oct; 37(15):1828-32. PubMed ID: 11576835
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
    Schmidt J; Abel U; Debus J; Harig S; Hoffmann K; Herrmann T; Bartsch D; Klein J; Mansmann U; Jäger D; Capussotti L; Kunz R; Büchler MW
    J Clin Oncol; 2012 Nov; 30(33):4077-83. PubMed ID: 23008325
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study.
    Burch PA; Block M; Schroeder G; Kugler JW; Sargent DJ; Braich TA; Mailliard JA; Michalak JC; Hatfield AK; Wright K; Kuross SA
    Clin Cancer Res; 2000 Sep; 6(9):3486-92. PubMed ID: 10999733
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy.
    di Bartolomeo M; Bajetta E; de Braud F; Bochicchio AM; Gebbia V; Bozzetti F; Doci R; Bonfanti G; Cozzaglio L
    Oncology; 1995; 52(1):41-4. PubMed ID: 7800341
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II trial of low-dose cyclophosphamide, leucovorin, high-dose 5-fluorouracil 24-hour continuous infusion and tamoxifen in advanced biliary tract cancer.
    Eckel F; Lersch C; Assmann G; Schulte-Frohlinde E
    Ann Oncol; 2000 Jun; 11(6):762-3. PubMed ID: 10942070
    [No Abstract]   [Full Text] [Related]  

  • 53. Response to doxorubicin/methotrexate/fluorouracil in advanced adenocarcinoma of pancreas or biliary tract.
    Pyrhönen S; Valtonen M
    Lancet; 1990 Jul; 336(8707):127. PubMed ID: 1975317
    [No Abstract]   [Full Text] [Related]  

  • 54. Continuous hepatic arterial infusion chemotherapy for liver metastasis from biliary tract and pancreatic cancers.
    Kato Y; Tsuyuki A; Kikuchi K; Tokuyama J; Kurihara N; Kumamoto Y; Fujishiro Y; Ebinuma H
    Anticancer Res; 2005; 25(1B):477-82. PubMed ID: 15816615
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract.
    Zabernigg A; Giesinger JM; Pall G; Gamper EM; Gattringer K; Wintner LM; Sztankay MJ; Holzner B
    BMC Cancer; 2012 Sep; 12():390. PubMed ID: 22950826
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chemotherapy of biliary tract cancer with mitomycin-C and 5-fluorouracil biologically modulated by folinic acid. A phase II study.
    Polyzos A; Nikou G; Giannopoulos A; Toskas A; Kalahanis N; Papargyriou J; Michail P; Papachristodoulou A
    Ann Oncol; 1996 Aug; 7(6):644-5. PubMed ID: 8879384
    [No Abstract]   [Full Text] [Related]  

  • 57. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial.
    Mackay TM; Latenstein AEJ; Augustinus S; van der Geest LG; Bogte A; Bonsing BA; Cirkel GA; Hol L; Busch OR; den Dulk M; van Driel LMJW; Festen S; de Groot DA; de Groot JB; Groot Koerkamp B; Haj Mohammad N; Haver JT; van der Harst E; de Hingh IH; Homs MYV; Los M; Luelmo SAC; de Meijer VE; Mekenkamp L; Molenaar IQ; Patijn GA; Quispel R; Römkens TEH; van Santvoort HC; Stommel MWJ; Venneman NG; Verdonk RC; van Vilsteren FGI; de Vos-Geelen J; van Werkhoven CH; van Hooft JE; van Eijck CHJ; Wilmink JW; van Laarhoven HWM; Besselink MG;
    JAMA Surg; 2024 Apr; 159(4):429-437. PubMed ID: 38353966
    [TBL] [Abstract][Full Text] [Related]  

  • 58. P-move: a randomized control trial of exercise in patients with advanced pancreatic or biliary tract cancer (aPBC) receiving beyond first-line chemotherapy.
    De Lazzari N; Götte M; Kasper S; Meier E; Schuler M; Pogorzelski M; Siveke JT; Tewes M
    Support Care Cancer; 2024 Jun; 32(7):437. PubMed ID: 38879700
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Ⅰ. Recent Trends in Chemotherapy followed by Surgery for Patients with Locally Advanced Biliary-Pancreatic Cancer].
    Takano S; Kuboki S; Takayashiki T; Suzuki D; Sakai N; Hosokawa I; Mishima T; Konishi T; Nishino H; Nakada S; Miyazaki M; Ohtsuka M
    Gan To Kagaku Ryoho; 2022 Oct; 49(10):1054-1058. PubMed ID: 36281595
    [No Abstract]   [Full Text] [Related]  

  • 60. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial.
    Tröger W; Galun D; Reif M; Schumann A; Stanković N; Milićević M
    Dtsch Arztebl Int; 2014 Jul; 111(29-30):493-502, 33 p following 502. PubMed ID: 25142075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.